Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
Cancer Chemotherapy and Pharmacology
|
January 22, 2002
Phase I clinical and pharmacokinetic trial of irofulven
J P Thomas, R Arzoomanian, D Alberti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer
H I Robins, K Tutsch, D M Katschinski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2000
Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day
G H Ripple, M N Gould, R Z Arzoomanian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2000
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies
L Ochoa, H I Hurwitz, G Wilding, et al.
The New England Journal of Medicine
|
October 8, 1998
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
M A Eisenberger, B A Blumenstein, E D Crawford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2011
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
A J Zurita, D J George, N D Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients
H I Robins, D Rushing, M Kutz, et al.
Cancer Chemotherapy and Pharmacology
|
April 1, 1999
A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia
H I Robins, D M Katschinski, W Longo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
D J Jonker, L S Rosen, M B Sawyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 1999
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group
G J Bubley, M Carducci, W Dahut, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
Cancer Chemotherapy and Pharmacology
|
January 22, 2002
Phase I clinical and pharmacokinetic trial of irofulven
J P Thomas, R Arzoomanian, D Alberti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer
H I Robins, K Tutsch, D M Katschinski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2000
Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day
G H Ripple, M N Gould, R Z Arzoomanian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2000
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies
L Ochoa, H I Hurwitz, G Wilding, et al.
The New England Journal of Medicine
|
October 8, 1998
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
M A Eisenberger, B A Blumenstein, E D Crawford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2011
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
A J Zurita, D J George, N D Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients
H I Robins, D Rushing, M Kutz, et al.
Cancer Chemotherapy and Pharmacology
|
April 1, 1999
A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia
H I Robins, D M Katschinski, W Longo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
D J Jonker, L S Rosen, M B Sawyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 1999
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group
G J Bubley, M Carducci, W Dahut, et al.
Page
of 11